In 2023, the FDA approved tirzepatide for obesity, which, according to Gratzl and colleagues, contributed to an increase in prescribing trends of GLP-1 medications
Both public and private payers use cost containment policies to control the amount and mix of drugs included under the prescription drug benefit, which may be administered by a pharmacy benefit manager, or PBM
Enzyme activity in the gut varies among individuals and among populations, and can lead to variations in the initial response to acarbose treatment [75]
A common question that comes up in Canadian peptide communities is whether a growth hormone secretagogue stack (CJC-1295 plus Ipamorelin) paired with AOD-9604 would work better than the Retatrutide combination
10.1530/JRF.0.0360009 42 Vallet-BuisanM.MeccaR.JonesC.CowardK.YesteM
Anini Y, Fu-Cheng X, Cuber JC, Kervran A, Chariot J, Roz C